Tampa’s Moffitt Cancer Center is forging an international partnership with Japan’s largest CRO, CMIC Group, to improve the ability of both organizations to run global cancer trials. Read more below: https://lnkd.in/erHGq3M3 #cro #cancercenter #cropartnership
Mantell Associates
Executive Search Services
City of London, England 88,743 followers
Multidiscipline Global Life Science and Pharmaceutical Headhunting Firm.
About us
Mantell Associates is a multi-discipline headhunting firm focused on providing both permanent and contract recruitment services globally, to the Biotech, Pharmaceutical, CDMO, CRO, Diagnostics, Animal Health, Consulting, Medical Device and MedTech sectors. With success ranging across C-Suite, Commercial, Technical Operations, Scientific, Clinical, Quality and Regulatory, we pride ourselves on our ability to bring the top talent to our clients, and the best opportunities to the top talent. Our services span across our Partnership Service, Contingency, Project Management and Contract models, meaning that we can cater to our client’s every requirement.
- Website
-
www.mantellassociates.com
External link for Mantell Associates
- Industry
- Executive Search Services
- Company size
- 51-200 employees
- Headquarters
- City of London, England
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Contract Development Manufacturing Organisations, Contract Manufacturing Organisations, Preclinical, Active Pharmaceutical Ingredients, Cell & Gene Therapy, Finished Dosage Forms, Biologics, Toxicology, Pharmacology, Oncology, CDMO, CMO, Biomarkers, Vaccines, Contract Research Organisation, Clinical Trial Supplies, Bioanalytics, Bioanalysis, Fine Chemicals, and Highly Potent Active Pharmaceutical Ingredients
Locations
-
Primary
150 Minories
City of London, England EC3N 1LS, GB
-
2 S Biscayne Blvd
Miami, Florida 33131, US
-
Rigistrasse 3
Zug, 6300, CH
Employees at Mantell Associates
Updates
-
With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential blockbuster in tow. Organon is set to acquire Roivant Sciences’ immuno-dermatology subsidiary Dermavant Sciences for up to $1.2 billion, the companies announced Wednesday. Under the terms of the deal—which is expected to close in the fourth quarter—Organon will dish out an upfront payment of $175 million. Read more below: https://lnkd.in/e8HUYDa2 #pharmaacquisition #investment #healthnews
Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama
fiercepharma.com
-
Apply now! Business Development Director - CRO - USA. Mantell Associates has partnered with an expert CRO who is seeking a Director of Business Development to strengthen its Commercial team. In this role, you will oversee the entire product and service portfolio and take immediate responsibility for assigned customers. Apply for this role online - https://lnkd.in/ed7BHDTf - or contact Aaron Dudley on 44 (0)20 3854 7700. #bdjobs #crojobs #businessdevelopmentjobs
-
Ahead of CPHI 2024, hosted in Milan in a couple of weeks time, Aaron Dudley delves into what attendees are most eager to gain from this year's event, and 8 key take aways to consider. As one of the largest and most influential events in the pharmaceutical industry, CPHI continues to be a focal point for professionals, innovators, and key stakeholders worldwide. Read more below: https://lnkd.in/eseW-gy9 #cphi #cphi2024 #pharmaconference
CPHI 2024: Key Take Aways?
https://www.mantellassociates.com
-
With a hefty investment led by Bain Capital and a new commercial facility on the horizon, growing CDMO Serán BioScience is looking to bridge the gap between clinic and market for its customers. Read more below: https://lnkd.in/ezezTXY8 #pharmainvestment #pharmafunding #cdmonews
CDMO Serán snags $200M Bain-led investment to build its first commercial facility
fiercepharma.com
-
A moment of appreciation for our incredible villa stay in Hvar! Our top performers had the pleasure of staying in one of the most beautiful villas in the centre of Hvar, with amazing views overlooking the sea. Complete with private pool and hot tub, gym and massage room. Our High Rollers incentive is a way to celebrate success and show appreciation for our employees - huge congratulations to everyone who qualified! #recruitmentincentives #recruitmentlondon #workincentive
-
5
-
Amid all the AI hype, pharma marketers are taking a more cautious approach to implementing the technology. In interviews last week, marketing leaders from Bayer, Daiichi Sankyo and argenx discussed that slower integration of AI as well as the many opportunities for the technology in the realm of pharma marketing. Read more below: https://lnkd.in/eANaExFg #biopharma #marketingnews #ai
Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
fiercepharma.com
-
New opportunity! International Sales Director - Biotech - San Diego. Mantell Associates has partnered with a leading Biotech who is seeking an International Sales Director who will be responsible for developing and executing strategic sales plans to drive growth and achieve revenue targets in the international market. Apply for this role online - https://lnkd.in/eeuihbpX - or contact Robin Mantell on 1 (786) 485 1298. #salesjobs #salesdirector #biotechjobs
-
GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 million for its “plug-and-play” tech developed in the lab of — and with cells from — George Church, Ph.D. Read more below: https://lnkd.in/eNHFEt3J #biotechnews #biotechfunding #celltherapy
From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform
fiercebiotech.com
-
Basilea Pharmaceutica’s work developing new antifungals has received a significant boost from the U.S. Department of Health and Human Services, which has signed off on up to $268 million of funding to the Swiss company over more than a decade. Read more below: https://lnkd.in/e-TkjhRv #pharmafunding #fundingnews #healthnews
Basilea scores $268M BARDA funding deal to work on antifungals, antibiotics
fiercebiotech.com